Targeting DNA Replication before it Starts: Cdc7 as a Therapeutic Target in p53-Mutant Breast Cancers

Treatment options for triple-receptor negative (ER−/PR−/Her2−) and Her2-overexpressing (ER−/PR−/Her2+) breast cancers with acquired or de novo resistance are limited, and metastatic disease remains incurable. Targeting of growth signaling networks is often constrained by pathway redundancy or growth...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rodriguez-Acebes, Sara, Proctor, Ian, Loddo, Marco, Wollenschlaeger, Alex, Rashid, Mohammed, Falzon, Mary, Prevost, A. Toby, Sainsbury, Richard, Stoeber, Kai, Williams, Gareth H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Investigative Pathology 2010
Assuntos:
Regular Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2947297/
https://ncbi.nlm.nih.gov/pubmed/20724597
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2353/ajpath.2010.100421
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados